Decreased muscle mass in nonalcoholic fatty liver disease: New evidence of a link between growth hormone and fatty liver disease?
Maureen M.J. Guichelaar, Michael R. Charlton – 6 February 2014
Maureen M.J. Guichelaar, Michael R. Charlton – 6 February 2014
Maureen M.J. Guichelaar, Michael R. Charlton – 6 February 2014
George Boon‐Bee Goh, Wan‐Cheng Chow, Renwei Wang, Jian‐Min Yuan, Woon‐Puay Koh – 6 February 2014 – Limited experimental and epidemiologic data suggest that coffee may reduce hepatic damage in chronic liver disease. The association between consumption of coffee and other beverages and risk of cirrhosis mortality was evaluated in the Singapore Chinese Health Study.
Dewei Ye, Yudong Wang, Huating Li, Weiping Jia, Kwan Man, Chung Mau Lo, Yu Wang, Karen S.L. Lam, Aimin Xu – 6 February 2014 – Acetaminophen (APAP) overdose is a leading cause of drug‐induced hepatotoxicity and acute liver failure worldwide, but its pathophysiology remains incompletely understood. Fibroblast growth factor 21 (FGF21) is a hepatocyte‐secreted hormone with pleiotropic effects on glucose and lipid metabolism. This study aimed to investigate the pathophysiological role of FGF21 in APAP‐induced hepatotoxicity in mice.
Claudio Puoti, Lia Bellis, Olga Mitidieri Costanza, Maria Giuseppa Elmo – 5 February 2014
Steven Schenker – 5 February 2014
David L. Wyles, Maribel Rodriguez‐Torres, Eric Lawitz, Mitchell L. Shiffman, Stanislas Pol, Robert W. Herring, Benedetta Massetto, Bittoo Kanwar, James D. Trenkle, Phil S. Pang, Yanni Zhu, Hongmei Mo, Diana M. Brainard, G. Mani Subramanian, John G. McHutchison, François Habersetzer, Mark S.
Constance E. Ruhl, Andy Menke, Catherine C. Cowie, James E. Everhart – 5 February 2014 – An association of hepatitis C virus (HCV) infection with diabetes has been reported in many studies, but few have been population based and applied standard criteria for diabetes diagnosis. We examined this relationship using recent population‐based data from the U.S. National Health and Nutrition Examination Survey. Adult participants (15,128) in the 1999‐2010 surveys had data on diabetes status and serum HCV antibody (anti‐HCV) or HCV RNA.
Ling Li, David Masica, Masaharu Ishida, Ciprian Tomuleasa, Sho Umegaki, Anthony N. Kalloo, Christos Georgiades, Vikesh K. Singh, Mouen Khashab, Stuart Amateau, Zhiping Li, Patrick Okolo, Anne‐Marie Lennon, Payal Saxena, Jean‐Francois Geschwind, Todd Schlachter, Kelvin Hong, Timothy M. Pawlik, Marcia Canto, Joanna Law, Reem Sharaiha, Clifford R. Weiss, Paul Thuluvath, Michael Goggins, Eun Ji Shin, Haoran Peng, Vivek Kumbhari, Susan Hutfless, Liya Zhou, Esteban Mezey, Stephen J. Meltzer, Rachel Karchin, Florin M.
Ling Li, David Masica, Masaharu Ishida, Ciprian Tomuleasa, Sho Umegaki, Anthony N. Kalloo, Christos Georgiades, Vikesh K. Singh, Mouen Khashab, Stuart Amateau, Zhiping Li, Patrick Okolo, Anne‐Marie Lennon, Payal Saxena, Jean‐Francois Geschwind, Todd Schlachter, Kelvin Hong, Timothy M. Pawlik, Marcia Canto, Joanna Law, Reem Sharaiha, Clifford R. Weiss, Paul Thuluvath, Michael Goggins, Eun Ji Shin, Haoran Peng, Vivek Kumbhari, Susan Hutfless, Liya Zhou, Esteban Mezey, Stephen J. Meltzer, Rachel Karchin, Florin M.